CHI ADVISORS LLC
Q3 2023 Form 13-F
NEW YORK, NEW YORK
CIK 0001791468
· CRD 304684
· SEC-registered investment adviser
$252.3M Reported Value Total
CHI ADVISORS LLC reports 6 total accounts under management (AUM). There are 6 discretionary accounts valued at $1,156,715,814, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
7 funds
· $1.2B gross asset value
Private Equity Fund: $1.2B
Source: Form ADV filed 2023-06-05
Reported value
$252.3M
Quarter over quarter
-17.8%
Holdings
26
Top-10 concentration
81.3%
Key People
Form ADV owners & control persons
Michael G Benwitt
GENERAL COUNSEL, CHIEF OPERATING OFFICER, COWEN INVESTMENT MANAGEMENT LLC
Ashley Paige Latourelle
CHIEF COMPLIANCE OFFICER
Elizabeth Rachel Rosman
HEAD OF INVESTMENT MANAGEMENT, COWEN INVESTMENT MANAGEMENT LLC
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2023 13F record
Q3 2023 13F filing summary
| Period of report | September 30, 2023 |
|---|---|
| Filed | November 13, 2023 |
| Form | 13F-HR |
| Reported value | $252.3M |
| Positions | 26 |
| Change in reported value | -23.4% |
| New positions | 4 |
| Exited positions | 3 |
| Position turnover | 24.1% |
| Top-10 concentration | 81.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2023 13F
Filed Nov 13, 2023
|
26 | $252.3M |
|
Q2 2023 13F
Filed Aug 11, 2023
|
25 | $329.6M |
|
Q1 2023 13F
Filed May 11, 2023
|
23 | $376.7M |
|
Q4 2022 13F
Filed Feb 13, 2023
|
22 | $375.5M |
|
Q3 2022 13F
Filed Nov 9, 2022
|
25 | $371.9M |
|
Q2 2022 13F
Filed Aug 12, 2022
|
25 | $261.8M |
|
Q1 2022 13F
Filed May 16, 2022
|
21 | $235.2M |
|
Q4 2021 13F
Filed Feb 11, 2022
|
20 | $301.3M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
19 | $342.6M |
|
Q2 2021 13F
Filed Aug 11, 2021
|
18 | $429.9M |
|
Q1 2021 13F
Filed May 14, 2021
|
21 | $499.5M |
|
Q4 2020 13F
Filed Feb 12, 2021
|
20 | $355.0M |
|
Q3 2020 13F
Filed Nov 12, 2020
|
21 | $281.1M |
|
Q2 2020 13F
Filed Aug 12, 2020
|
19 | $256.3M |
|
Q1 2020 13F
Filed May 14, 2020
|
13 | $42.4M |
|
Q4 2019 13F
Filed Feb 14, 2020
|
12 | $132.6M |
|
Q3 2019 13F
Filed Nov 12, 2019
|
13 | $102.7M |
Top 20 holdings · Q3 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | PLRX PLIANT THERAPEUTICS INC | $52.3M | 20.72% |
| 2 | RPTX REPARE THERAPEUTICS INC | $35.8M | 14.2% |
| 3 | CGEM CULLINAN ONCOLOGY INC | $30.9M | 12.25% |
| 4 | SLRN ACELYRIN INC | $23.0M | 9.12% |
| 5 | ORTX ORCHARD THERAPEUTICS PLC | $14.0M | 5.56% |
| 6 | LRMR LARIMAR THERAPEUTICS INC | $13.5M | 5.35% |
| 7 | KROS KEROS THERAPEUTICS INC | $13.0M | 5.15% |
| 8 | IKNA IKENA ONCOLOGY INC | $9.4M | 3.74% |
| 9 | RARE ULTRAGENYX PHARMACEUTICAL IN | $7.7M | 3.04% |
| 10 | CMPX COMPASS THERAPEUTICS INC | $5.6M | 2.21% |
| 11 | MLYS MINERALYS THERAPEUTICS INC | $5.4M | 2.14% |
| 12 | INZY INOZYME PHARMA INC | $5.3M | 2.11% |
| 13 | SYRS SYROS PHARMACEUTICALS INC | $5.1M | 2.03% |
| 14 | BPMC BLUEPRINT MEDICINES CORP | $4.7M | 1.85% |
| 15 | LABD DIREXION SHS ETF TR | $4.6M | 1.84% |
| 16 | TSVT 2SEVENTY BIO INC | $3.9M | 1.56% |
| 17 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | $3.4M | 1.36% |
| 18 | OVID OVID THERAPEUTICS INC | $3.3M | 1.32% |
| 19 | SGMT SAGIMET BIOSCIENCES INC | $3.1M | 1.22% |
| 20 | OMGA OMEGA THERAPEUTICS INC | $2.3M | 0.9% |
Values as reported on the Q3 2023 Form 13F. Every position is in the holdings table below.